Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lixte Biotechnology HoldingsLIXTW +4.74%34 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 2,304 Industrial Products companies, Lixte Biotechnology Holdings ranks worse than 43402.73% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lixte Biotechnology Holdings's
Operating Income
for the
three
months ended in Jun. 2026 was $-2.35 Mil. Lixte Biotechnology Holdings's Interest Expense for the
three
months ended in Jun. 2026 was $-0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Lixte Biotechnology Holdings's Interest Coverage or its related term are showing as below:
LIXTW's Interest Coverage is not ranked *
in the Industrial Products industry.
Industry Median: 14.625 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lixte Biotechnology Holdings Interest Coverage Related Terms
Lixte Biotechnology Holdings Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LIXTW vs CBAT, TGEN, STI: Interest Coverage Comparison
For the Electrical Equipment & Parts subindustry, Lixte Biotechnology Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings Interest Coverage vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Lixte Biotechnology Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Lixte Biotechnology Holdings did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Lixte Biotechnology Holdings (LIXTW) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lixte Biotechnology Holdings and its competitors. According to the industry distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 2304 companies in the Industrial Products industry.
Is Lixte Biotechnology Holdings' Interest Coverage too high?
Lixte Biotechnology Holdings' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 2304 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' Interest Coverage compare to CBAT and TGEN?
According to the Industrial Products industry distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 2304 companies for Interest Coverage. This places Lixte Biotechnology Holdings in the lower half of its industry. The industry median Interest Coverage is 14.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for an Industrial Products company?
The median Interest Coverage among Industrial Products companies is 14.63, based on 2,304 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lixte Biotechnology Holdings and its competitors. For the Industrial Products industry, the median Interest Coverage is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lixte Biotechnology Holdings's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score
Get the complete analysis for LIXTW
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIXTW has been successfully added to your 
